Invesco MSCI EAFE Income Advantage ETF Price & Performance (EFAA)

Steward Partners Investment Advisory LLC has acquired 13,046 shares of the Invesco MSCI EAFE Income Advantage ETF, valued at approximately $610,000. This move highlights the firm's strategic interest in equity-based income strategies. The ETF, launched in mid-2024, employs an options-based approach for both growth and risk management.1

Blue Trust Inc. reduced its stake in Maximus, Inc. by 29.4%, selling 385 shares in Q4. The institutional investor now holds 925 shares valued at $69,000. Maximus recently faced a stock decline of 1.2%, with its price dropping to $65.95, amidst a year-high of $93.97.2

Prime Medicine has emerged as a stronger investment pick compared to Achilles Therapeutics, according to analysts. With a consensus target price indicating a potential upside of 352.59%, Prime Medicine's genetic therapy innovations have drawn significant institutional support, owning 70.4% of its shares.3